Novel Therapeutic Agents for Relapsed Classical Hodgkin Lymphoma

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15695
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Novel Treatment Strategies for Patients With Relapsed Classical Hodgkin Lymphoma

Blood Reviews
OncologyHematology
2010English

CD30-targeted Oncolytic Viruses as Novel Therapeutic Approach Against Classical Hodgkin Lymphoma

Oncotarget
Oncology
2018English

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience

Acta Haematologica Polonica
OncologyHematology
2018English

Lymphocyte-Rich Classical Hodgkin Lymphoma

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2018English

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Evita: Phase I/Ii Study of Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

An Anaplastic T-Cell Lymphoma Mimicking Classical Hodgkin Lymphoma

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

Klinicka Onkologie
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy